A recent study has revealed that patients suffering from both COVID-19 and ST-elevation myocardial infarction (STEMI) face a significantly higher risk of mortality within a year compared to those dealing with STEMI alone. These findings were presented at a prominent cardiovascular symposium held in Montreal, underscoring crucial new insights into the long-term impact of COVID-19 on heart attack patients.
The North American COVID-19 Myocardial Infarction (NACMI) registry, the study’s source, is the inaugural effort to examine extended outcomes for individuals afflicted by both conditions. According to the data, individuals with both COVID-19 and STEMI are seven times more likely to suffer from severe complications such as in-hospital death, stroke, or recurrent myocardial infarction than those without COVID-19.
Conducted through a collaborative effort involving the Society for Cardiovascular Angiography and Interventions (SCAI) and the Canadian Association of Interventional Cardiology (CAIC), the registry collected data from 2,358 hospitalized STEMI patients across North America. The study categorized these patients into three groups: 623 COVID-19 positive, 694 COVID-19 negative, and 1,041 matched controls.
The results showed a stark difference in outcomes: patients with both conditions experienced a 67% increase in one-year mortality rates compared to those without the virus, highlighting the severe impact of COVID-19 on cardiovascular health. This pivotal study calls for increased clinical awareness and management strategies for patients with overlapping conditions.
